Although, our study focuses on understanding the immune corelates of BCG responsiveness, we propose that the enrichment of PD1+CD38+Tim3+ CD8+ T cells at the NMIBC tumor site is not solely related to BCG response, rather it stratifies patients with a high recurrence risk already at the baseline. This evidence concerns the gene HAVCR2 and neoplasm.